<DOC>
	<DOCNO>NCT01372384</DOCNO>
	<brief_summary>This open-label study ass efficacy safety Tarceva ( Erlotinib ) patient locally advance , metastatic recurrent non-small cell lung cancer receive previous chemotherapy disease present epidermal growth factor receptor mutation . Patients receive Tarceva 150 mg orally daily disease progression unacceptable toxicity occur .</brief_summary>
	<brief_title>A Study Tarceva ( Erlotinib ) Patients With Locally Advanced , Metastatic Recurrent Non-Small Cell Cancer Who Present Epidermal Growth Factor Receptor Mutations</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Locally advance ( Stage IIIB ) , metastatic ( Stage IV ) recurrent nonsmall cell lung cancer mutation tyrosine kinase domain epidermal growth factor receptor ( EGFR ) At least one measurable lesion accord RECIST criterion European Cooperative Oncology Group ( ECOG ) performance status 02 Adequate hematological , liver renal function Patients stable cerebral metastasis receive surgical radiotherapy eligible Previous chemotherapy therapy EGFR metastatic disease ( neoadjuvant adjuvant therapy radical surgery allow finalize &gt; /= 6 month enter study ) History another neoplasm except carcinoma situ cervix , adequately treat basal cell skin carcinoma , radically treat prostate carcinoma good prognosis ( Gleason &lt; /= 6 ) , another curatively treat neoplasm without evidence disease last 5 year Symptomatic cerebral metastasis Any significant ophthalmologic abnormality Use coumarins Pregnant breastfeed woman Preexisting parenchymal lung disease pulmonary fibrosis , lymphangiosis carcinomatosis ( presence disease )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>